Results 111 to 120 of about 5,328 (181)

Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions [PDF]

\ua9 2025 The AuthorsBackground: Entrectinib, a central nervous system (CNS)-penetrant TRK/ROS1 inhibitor, has demonstrated clinical activity in children with NTRK1/2/3 or ROS1 fusion-positive extracranial solid and CNS tumours.
Andre N, Armstrong AE, Bagchi A, Basu EM, Campbell-Hewson Q, Cardenas A, Casanova M, Ci B, Desai AV, Devlin CE, Fox E, Gajjar A, Hutchinson KE, Meneses-Lorente G, Robinson GW, Ryklansky C, van Tilburg CM, Wang H, Wu Y, Wulff J   +19 more
core  

Late Onset of Entrectinib-Related ST Elevation in the Setting of Alcohol Intoxication in a Patient With Metastatic Non-small Cell Lung Cancer: A Case Report and Literature Review. [PDF]

Cureus
Xia C, Kosmider S.
europepmc   +1 more source

Entrectinib binds to HMGB1 and activates cardiomyocyte autophagy by inhibiting OTUD5-MTORC1 signaling to induce cardiotoxicity. [PDF]

Autophagy
Gao Z, Zhang J, Fu H, Zhang S, Chen J, Zhou H, Chen X, Zhang X, Yan H, Yang B, He Q, Xu Z, Luo P.   +12 more
europepmc   +1 more source

Dramatic response to entrectinib in a rare glioneuronal tumor harboring an NTRK2 fusion. [PDF]

Oncologist
Akrout F, Bogumil H, Yedeas MD, Sievers P, Touat M, Achoura S.   +5 more
europepmc   +1 more source

Targeted Therapies and their Associated Molecular Alterations in the Treatment of Renal Cell Carcinoma [PDF]

Renal cell carcinoma, (RCC) the most prevalent of kidney cancers, is a relatively common cancer, constituting approximately 10% of all cancers in adults.
Dr. Priya Hays
core   +1 more source

First Report of Entrectinib as a Treatment Option for Pure Squamous Cell Carcinoma Harboring <i>ROS1</i> Rearrangement: Exploring the Role of Next-Generation Sequencing in Targeted Therapy. [PDF]

Int J Mol Sci
Tang YJ, Chen RH, Lu YS, Wu CE.
europepmc   +1 more source

Letter re: 'Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications' [PDF]

, 2021
Hatswell, AJ, Sullivan, WG
core   +1 more source

High-throughput transcriptomic screening reveals entrectinib as a repositioning opportunity in 19q12 autism spectrum disorder. [PDF]

Sci Rep
Guin D, Haditsch U, Bellucci JJ, Topka S, Dyer KE, Del Toro GAR, Blanco MR, Downs NF, Perfito N, Mahadevan A, Moxham CM.   +10 more
europepmc   +1 more source

Acquired MTAP Loss Following Entrectinib Resistance in ROS1-Rearranged NSCLC With CD74 Exon 3-ROS1 Exon 34 Fusion. [PDF]

Thorac Cancer
Haraguchi Hashiguchi M, Tanino M, Yoneda S, Asaoka M, Kagyo J, Katayama M, Terai H, Nakamura K, Nishihara H, Fukunaga K.   +9 more
europepmc   +1 more source

Neurological adverse events of ROS1 inhibitors for non-small cell lung cancer: data from the FDA adverse event reporting system. [PDF]

Front Neurol
Wei X, Lai Q, Zheng L.
europepmc   +1 more source